Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie — Clinical Trial Site

104 Registered trials

49 Currently recruiting

Organisation

Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie

Location

Koszalin, Poland

Identifier

ORG-100041103

Address

Ul. Tytusa Chalubinskiego 7, 75-581, Poland

Departments

5701: Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
5702: Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
5704: Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
5705: Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
Chemotherapy clinic with a day ward
Department of Chemotherapy
Department of Clinical Oncology with a Subdivision of One-day Chemotherapy
Klinika Chemioterapii z oddziałem dziennym
Medical Oncology
N/A
NA
Oddzial Dzienny Chemioterapii
Oddzial Onkologii Klinicznej z Pododdzialem Chemioterapii Jednodniowej
Oddzial Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Dzienny Chemioterapii
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej,
Oddział Onkologii Klinicznej z Pododdziałem Chemioterapii Jednodniowej.
Oddział Onkologii Klinicznej z Pododziałem Chemioterapii Jednodniowej
Oddział Onkologii Klinicznej z Pododziałem Chemioterapii Jednodnioweji
Oncology
Szpital Wojewódzki im. Mikołaja Kopernika w Koszalinie Oddział Dzienny Chemioterapii

Clinical trials at this site (104)

Search interface

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis. Pending

2024-519298-21-00 Cancer-Associated Thrombosis (CAT). 5
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cel… Pending

2024-519786-22-01 metastatic non-small cell lung cancer (NSCLC) 9
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Carcinoma, Transitional Cell 5
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Pending

2025-523521-18-00 Metastatic Colorectal Cancer 5
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 10 2026-05-20
A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab. Recruiting

2025-521639-34-00 • Non-small cell lung cancer (Stage III, unresectable) 3 2026-04-20
A clinical study of MK-1084 with other treatments for non-small cell lung cancer (MK-3475-01F) Recruiting

2024-512248-47-00 Non-small Cell Lung Cancer (NSCLC) 9 2026-04-15
A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting

2025-520902-37-00 Non-small cell lung cancer stage IV 4 2026-04-01
A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting

2025-521939-36-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 4 2026-03-03
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Hormone receptor positive breast cancer 5 2025-10-17
A clinical study of treatments for non-small cell lung cancer (MK-3475-01I) Recruiting

2024-518839-11-00 Stage IV Squamous Non-Small Cell Lung Cancer 4 2025-08-25
A study to compare effects and safety of CT-P51 and Keytruda in patients with previously untreated metastatic lung cancer Recruiting

2024-514048-98-00 Previously Untreated Metastatic Non-Squamous Non-Small 5 2025-01-30
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Metastatic Castration-Sensitive Prostate Cancer (mCSPC) 5 2024-06-27
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting

2025-523085-24-00 Biliary Tract Cancer 5 2026-04-13
(Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting

2024-520026-11-00 Metastatic Prostate Cancer 7 2026-03-19
Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting

2024-518210-81-00 Advanced Hepatocellular Carcinoma 5 2026-03-18
Safety and efficacy of BNT327, an investigational therapy, in combination with chemotherapy for patients with untreated small-cell lung canc… Recruiting

2024-515765-34-00 English First-line extensive-stage small-cell lung canc 5 2026-02-04
A Study to Learn About the Investigational Medicine Called Mevrometostat (PF-06821497) in Men With Metastatic Castration-Sensitive Prostate … Recruiting

2024-519369-24-00 METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER 5 2026-01-29
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Prostate Cancer 5 2025-12-10
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-033) Recruiting

2024-517136-21-00 Renal Cell Carcinoma 5 2025-12-05
A clinical study of MK-1084 in people with advanced solid tumors (MK 1084-014) Recruiting

2025-521737-91-00 Neoplasm malignant with KRAS G12C mutation 4 2025-11-25